Secukinumab is recommended as an option for adults with a Psoriasis Area Severity Index (PASI) score of 10 or more and a Dermatology Life Quality Index (DLQI) score greater than 10.
NICE technology appraisal TA350
Treatment with secukinumab should be stopped if an adequate response is not achieved by 12 weeks. An adequate response is defined as either a 75% reduction in PASI score, or a 50% reduction in PASI score accompanied by a 5-point reduction in DLQI score.
Clinicians may need to adjust the DLQI score if the patient has any disabilities or communication difficulties that could affect the assessment.
NICE's decision is conditional on the manufacturer providing secukinumab with the discount agreed in the patient access scheme.